RPS20P35: A Promising Drug Target / Biomarker (G100271566)

Target Name: RPS20P35

NCBI ID: G100271566

RPS20P35

Other Name(s): ribosomal protein S20 pseudogene 35 | RPS20_18_1544 | Ribosomal protein S20 pseudogene 35

RPS20P35: A Promising Drug Target / Biomarker

RPS20P35 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its full name is ratpadding protein 20 (RPP20), and it is a member of the PIDC family of proteins. PIDC proteins are known for their role in cell signaling and inflammation. RPP20 is a 20-kDa protein that is expressed in the brain and other tissues of the body.

The Importance of RPS20P35

RPS20P35 is a key protein that is involved in several important cellular processes in the body. One of its most significant functions is its role in the regulation of pain. RPP20 is known to play a role in the regulation of pain perception and neuroinflammation.

RPP20 is also involved in the regulation of inflammation in the brain. It has been shown to play a role in the regulation of neuroinflammation, which is inflammation that occurs in the brain. RPP20 has been shown to reduce neuroinflammation by regulating the production of pro-inflammatory cytokines.

Another function of RPS20P35 is its role in cell signaling. RPP20 is involved in several signaling pathways, including the TGF-β pathway and the NF-kappa-B pathway. These pathways are important for the regulation of cell growth, differentiation, and inflammation.

Drug Targeting and Biomarker

RPS20P35 is a drug target that can be used to treat several neurological and psychiatric disorders. Its role in the regulation of pain and inflammation makes it an attractive target for drug development.

One of the most promising uses of RPS20P35 is its potential as a treatment for chronic pain. Chronic pain can be caused by a variety of conditions, including diabetes, fibromyalgia, and multiple sclerosis. RPP20 has been shown to be involved in the regulation of pain perception and neuroinflammation, which makes it a potential target for the treatment of chronic pain.

Another promising use of RPS20P35 is its potential as a biomarker for several neurological disorders. RPP20 is expressed in several tissues of the body, including the brain, heart, and kidneys. Its expression is often reduced in diseases, such as Alzheimer's disease and Parkinson's disease. This makes RPP20 a potential biomarker for these disorders.

Conclusion

RPS20P35 is a protein that is involved in several important cellular processes in the body. Its role in the regulation of pain and inflammation makes it an attractive target for drug development. The potential use of RPS20P35 as a treatment for chronic pain and as a biomarker for several neurological disorders makes it a promising protein for further research.

Protein Name: Ribosomal Protein S20 Pseudogene 35

The "RPS20P35 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPS20P35 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets